시장보고서

상품코드

1574936

직접 작용형 항바이러스제 시장 : 유형별, 적응증별, 투여경로별, 유통별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율 예측(2024-2032년)

Direct-acting Antiviral Drug Market, By Type, By Indication, By Route of Administration, By Distribution, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: 2024년 10월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 260 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

직접 작용형 항바이러스제 시장 규모는 2023년 284억 932만 달러로 2024년부터 2032년까지 연평균 복합 성장률(CAGR) 5.50%로 확대

직접 작용형 항바이러스제 시장 - 시장 역학

간염과 HIV에 대한 인식과 스크리닝 프로그램 증가

직접 작용형 항바이러스제(DAA) 시장은 간염과 HIV 감염의 유병률 증가 등 몇 가지 주요 요인에 의해 확대되고 있습니다. 이러한 질병에 대한 인식이 높아짐에 따라 검진을 받는 사람이 늘어나고 진단률의 상승으로 이어지고 있습니다. 헬스케어에 대한 접근성 개선과 이러한 질병에 대한 교육도 원인이 되고 있습니다. 게다가, 최근의 의약품 개발 동향에 의해 보다 효과적이고 즉효성이 있는 치료제가 개발되어 높은 주목을 끌고 있습니다.

미국 질병 예방관리센터(CDC)는 2021년에는 B형 및 C형 간염 환자의 약 25%가 진단된다고 보고하고 있으며, 효과적인 치료법의 긴급 필요성이 부각되고 있다 합니다. 이러한 의식의 향상과 스크리닝 프로그램의 개선은 바이러스 감염을 효과적으로 관리·치료하는데 있어서 매우 중요합니다. 그 결과, DAA에 대한 수요는 증가의 길을 따라 항바이러스 치료의 미래를 형성하게 됩니다.

직접 작용형 항바이러스제 시장 - 주요 인사이트

우리 리서치 애널리스트의 분석에 따르면 세계 시장은 예측 기간(2024-2032년)에 약 5.50%의 CAGR로 매년 성장할 것으로 추정됩니다.

유형별로, NS5A 단백질은 2023년에 가장 큰 시장 점유율을 나타냈습니다.

적응증별로는 2023년에는 C형 간염 바이러스가 주요 유형이 되고 있습니다.

투여 경로별로, 경구제는 2023년의 주요 유형이었습니다.

유통별로는 2023년에는 병원 약국이 주요 유형이 되고 있습니다.

지역별로는 북미가 2023년 매출에서 최고

직접 작용형 항바이러스제 시장 - 세분화 분석 :

직접 작용형 항바이러스제 세계 시장은 유형, 적응증, 투여 경로, 유통, 지역에 따라 세분화됩니다.

시장은 유형에 따라 세 가지 범주로 나뉩니다. NS3/4A 프로테아제, NS5A 단백질, NS5B RNA 의존성 RNA 중합효소입니다. NS5A Protein 부문은 직접 작용형 항바이러스제 시장에서 가장 두드러집니다. NS5A 억제제는 C형 간염 치료에 매우 효과적이며 많은 성공적인 치료 요법에 사용되기 때문입니다. NS5A 억제제는 바이러스 복제 및 집합을 억제하고 환자의 예후를 개선합니다. NS5A 억제제를 포함한 병용 요법에 대한 수요가 증가함에 따라,이 부문은 우위를 차지합니다. 그 결과 NS5A 단백질 의약품은 C형 간염 치료 옵션을 넓히고 환자의 건강 상태를 개선하는데 있어서 매우 중요한 존재가 되고 있습니다.

시장은 적응증에 의해 4개의 범주로 분류됩니다: C형 간염 바이러스, HIV 감염/AIDS, 인플루엔자, 예방제입니다. C형 간염 바이러스 부문은 직접 작용형 항바이러스제 시장에서 가장 두드러집니다. C형 간염은 세계 수백만 명이 앓고 있으며 효과적인 치료에 대한 강한 수요가 발생하고 있기 때문입니다. C형 간염에 특화된 직접 작용형 항바이러스제는 높은 치유율을 나타내며 널리 사용되고 있습니다. C형 간염의 인지도가 높아짐에 따라, 이러한 치료를 요구하는 환자도 증가하고, 이 부문이 주류가 되고 있습니다. 전반적으로 C 형 간염 치료제는 건강 상태를 개선하고 질병의 확산을 억제하는 데 중요한 역할을합니다.

직접 작용형 항바이러스제 시장 - 지리적 통찰

직접 작용형 항바이러스제(DAA) 시장은 C형 간염과 HIV의 효과적인 치료에 대한 수요가 높은 북미, 특히 미국이 가장 큽니다. 유럽이 이에 이어 독일, 프랑스, 영국 등이 항바이러스 요법에 투자하고 있습니다. 아시아태평양은 특히 중국과 인도와 같은 국가에서 의료에 대한 인식과 접근이 증가하고 있으며 급성장하는 지역입니다. 라틴아메리카도 바이러스 감염증 대책을 목적으로 한 헬스케어에 대한 대처가 활발해지고 있어 가능성을 나타내고 있습니다. 중동 및 아프리카 시장 점유율은 작지만 건강 관리 인프라 개선으로 점차 확대되고 있습니다. 전반적으로 북미가 주도하고 있지만 다른 지역도 DAA 시장에서 크게 발전하고 있습니다.

직접 작용형 항바이러스제 시장 - 경쟁 구도:

직접 작용형 항바이러스제(DAA) 시장은 C형 간염과 HIV의 효과적인 치료로 알려진 길리아드사이언시스나 아비 등 대기업이 견인하고 있습니다. Merck, Bristol-Myers Squibb와 같은 다른 기업들은 경쟁력을 유지하기 위해 기술 혁신과 연구에 주력하여 다양한 항바이러스제 옵션을 제공합니다. 많은 기업들이 제품 라인을 강화하고 더 넓은 시장에 진출하기 위해 파트너십을 맺고 있습니다. 특허가 끊어지면 Mylan, Hetero Labs와 같은 제네릭 의약품 제조업체가 진입하여 저가의 대체품을 제공하게 됩니다. 시장은 세계적으로 확대되고 있으며, 저렴한 가격으로 치료를 받을 수 있도록 하는 것이 중시되고 있습니다. 기업은 규제 문제에 직면하고 있으며, 승인을 위해서는 대규모 임상시험이 필요합니다. 전반적으로 이 상황은 역동적이며 치열한 경쟁과 환자 관리 개선을위한 노력이 특징입니다.

소개
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제12장 주요 벤더 분석 - 직접 작용형 항바이러스제 업계

경쟁 대시보드
기업 프로파일
- Gilead Sciences
- AbbVie
- Merck &Co.
- Bristol-Myers Squibb
- Johnson &Johnson
- GlaxoSmithKline
- AstraZeneca
- Roche
- Novartis
- ViiV Healthcare
- Eisai
- Hetero Labs
- Mylan
- Fujifilm Toyama Chemical
- Sofinnova Partners

제13장 애널리스트의 전방위 전망

JHS 24.11.06

REPORT HIGHLIGHT

Direct-acting Antiviral Drug Market size was valued at USD 28,409.32 Million in 2023, expanding at a CAGR of 5.50% from 2024 to 2032.

The direct-acting antiviral (DAA) drug market focuses on medications that directly target and block the virus that causes hepatitis and HIV. These drugs work by interfering with the virus's ability to multiply, helping to clear the infection from the body. The drugs are important because they often have fewer side effects and work faster than older treatments. This makes them a preferred option for many patients. As awareness of these diseases grows, more people are seeking DAA drugs, leading to an increase in market demand. Overall, these drugs play a crucial role in improving health outcomes for those affected by viral infections.

Direct-acting Antiviral Drug Market- Market Dynamics

Growing awareness and screening programs for hepatitis and HIV.

The market for direct-acting antiviral (DAA) drugs is expanding due to several key drivers, including the increasing prevalence of hepatitis and HIV infections. As awareness of these diseases grows, more people are getting screened, leading to higher diagnosis rates. Improved healthcare access and education about these conditions are also contributing factors. Moreover, recent advancements in drug development have resulted in more effective treatments that act quickly, making them highly sought after.

The Centers for Disease Control and Prevention (CDC) reported that, in 2021, about 25% of people living with hepatitis B and C were diagnosed, highlighting the urgent need for effective therapies. This rising awareness and improved screening programs are crucial for managing and treating viral infections effectively. As a result, the demand for DAAs continues to grow, shaping the future of antiviral treatments.

Direct-acting Antiviral Drug Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.50% over the forecast period (2024-2032)

Based on Type segmentation, The NS5A Protein was predicted to show maximum market share in the year 2023

Based on Indication segmentation, Hepatitis C virus was the leading type in 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

Based on Distribution segmentation, Hospital Pharmacy was the leading type in 2023

based on region, North America was the leading revenue generator in 2023

Direct-acting Antiviral Drug Market- Segmentation Analysis:

The Global Direct-acting Antiviral Drug Market is segmented based on Type, Indication, Route of Administration, Distribution, and Region.

The market is divided into three categories based on Type: NS3/4A Protease, NS5A Protein, and NS5B RNA-Dependent RNA Polymerase. The NS5A Protein segment is the most prominent in the direct-acting antiviral drugs market. This is because NS5A inhibitors are highly effective in treating hepatitis C and are used in many successful treatment regimens. They help block the virus's ability to replicate and assemble, leading to better outcomes for patients. The growing demand for combination therapies that include NS5A inhibitors makes this segment dominant. As a result, NS5A Protein drugs are crucial for advancing hepatitis C treatment options and improving patient health.

The market is divided into four categories based on Indications: Hepatitis C Virus, HIV Infection/AIDS, Influenza, and Prophylaxis. The Hepatitis C virus segment is the most prominent in the direct-acting antiviral drug market. This is because hepatitis C affects millions of people worldwide, creating a strong demand for effective treatments. Direct-acting antivirals specifically designed for hepatitis C have shown high cure rates and are widely used. As awareness about the disease increases, more patients are seeking these treatments, making this segment dominant. Overall, hepatitis C drugs play a crucial role in improving health outcomes and reducing the disease's spread.

Direct-acting Antiviral Drug Market- Geographical Insights

The direct-acting antiviral (DAA) drug market is largest in North America, particularly the United States, where there is high demand for effective treatments for hepatitis C and HIV. Europe follows closely, with countries like Germany, France, and the UK investing in antiviral therapies. Asia-Pacific is a rapidly growing region, driven by increasing awareness and access to healthcare, especially in countries like China and India. Latin America also shows potential, with rising healthcare initiatives aimed at combating viral infections. The Middle East and Africa have a smaller market share but are gradually expanding due to improved healthcare infrastructure. Overall, North America leads, but other regions are making significant progress in the DAA market.

Direct-acting Antiviral Drug Market- Competitive Landscape:

The direct-acting antiviral (DAA) drug market is led by major players like Gilead Sciences and AbbVie, known for their effective treatments for hepatitis C and HIV. Other companies, including Merck and Bristol-Myers Squibb, also offer a variety of antiviral options, focusing on innovation and research to stay competitive. Many firms form partnerships to enhance their product lines and reach broader markets. As patents expire, generic manufacturers like Mylan and Hetero Labs enter the scene, providing lower-cost alternatives. The market is expanding globally, with a strong emphasis on making treatments affordable and accessible. Companies face regulatory challenges, needing extensive clinical trials for approval. Overall, the landscape is dynamic, marked by fierce competition and a commitment to improving patient care.

Recent Developments:

In September 2024, Cocrystal Pharma successfully advanced its oral pan-viral protease inhibitor, CDI-988, into Phase 1 multiple-ascending dose trials, which will evaluate the drug's safety, tolerability, and optimal dosing in healthy volunteers.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Gilead Sciences
AbbVie
Merck & Co.
Bristol-Myers Squibb
Johnson & Johnson
GlaxoSmithKline
AstraZeneca
Roche
Novartis
ViiV Healthcare
Eisai
Hetero Labs
Mylan
Fujifilm Toyama Chemical
Sofinnova Partners

GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

NS3/4A Protease
NS5A Protein
NS5B RNA-Dependent RNA polymerase

GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

Hepatitis C Virus
HIV Infection/ AIDS
Influenza
Prophylaxis

GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Intravenous
Oral
Subcutaneous
Topical

GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2019 - 2032

Hospital Pharmacy
Online Drug Store
Retail Pharmacy

GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Direct-acting Antiviral Drug Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Direct-acting Antiviral Drug Market Snippet by Type
- 2.1.2. Direct-acting Antiviral Drug Market Snippet by Indication
- 2.1.3. Direct-acting Antiviral Drug Market Snippet by Route of Administration
- 2.1.4. Direct-acting Antiviral Drug Market Snippet by Distribution
- 2.1.5. Direct-acting Antiviral Drug Market Snippet by Country
- 2.1.6. Direct-acting Antiviral Drug Market Snippet by Region
2.2. Competitive Insights

3. Direct-acting Antiviral Drug Key Market Trends

3.1. Direct-acting Antiviral Drug Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Direct-acting Antiviral Drug Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Direct-acting Antiviral Drug Market Opportunities
3.4. Direct-acting Antiviral Drug Market Future Trends

4. Direct-acting Antiviral Drug Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Direct-acting Antiviral Drug Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Direct-acting Antiviral Drug Market Landscape

6.1. Direct-acting Antiviral Drug Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Direct-acting Antiviral Drug Market - By Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
- 7.1.2. NS3/4A Protease
- 7.1.3. NS5A Protein
- 7.1.4. NS5B RNA-Dependent RNA polymerase

8. Direct-acting Antiviral Drug Market - By Indication

8.1. Overview
- 8.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
- 8.1.2. Hepatitis C Virus
- 8.1.3. HIV Infection/ AIDS
- 8.1.4. Influenza
- 8.1.5. Prophylaxis

9. Direct-acting Antiviral Drug Market - By Route of Administration

9.1. Overview
- 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
- 9.1.2. Intravenous
- 9.1.3. Oral
- 9.1.4. Subcutaneous
- 9.1.5. Topical

10. Direct-acting Antiviral Drug Market - By Distribution

10.1. Overview
- 10.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
- 10.1.2. Hospital Pharmacy
- 10.1.3. Online Drug Store
- 10.1.4. Retail Pharmacy

11. Direct-acting Antiviral Drug Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Direct-acting Antiviral Drug Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Direct-acting Antiviral Drug Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.3.9. Italy
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.3.9.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.9.6. Italy Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.3.10. United Kingdom
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.3.10.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.10.6. United Kingdom Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.3.11. France
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.3.11.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.11.6. France Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.3.12. Russia
  - 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.3.12.3. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Russia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.3.13. Netherlands
  - 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.3.13.3. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.13.5. Netherlands Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.3.15. Poland
  - 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.3.15.3. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Poland Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.3.16. Rest of Europe
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Rest of the Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Direct-acting Antiviral Drug Key Manufacturers in Asia Pacific
- 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.4.5. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.4.7. Asia Pacific Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.4.8. India
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.4.8.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.8.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.8.6. India Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.4.9. China
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.4.9.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.9.6. China Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.4.13. Thailand
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Thailand Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.4.14. Indonesia
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Indonesia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.5. Latin America
- 11.5.1. Overview
- 11.5.2. Direct-acting Antiviral Drug Key Manufacturers in Latin America
- 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.5.5. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.5.7. Latin America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa
- 11.6.1. Overview
- 11.6.2. Direct-acting Antiviral Drug Key Manufacturers in Middle East and Africa
- 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.6.7. Middle East and Africa Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Direct-acting Antiviral Drug Industry

12.1. Competitive Dashboard
12.2. Company Profiles
- 12.2.1. Gilead Sciences
- 12.2.2. AbbVie
- 12.2.3. Merck & Co.
- 12.2.4. Bristol-Myers Squibb
- 12.2.5. Johnson & Johnson
- 12.2.6. GlaxoSmithKline
- 12.2.7. AstraZeneca
- 12.2.8. Roche
- 12.2.9. Novartis
- 12.2.10. ViiV Healthcare
- 12.2.11. Eisai
- 12.2.12. Hetero Labs
- 12.2.13. Mylan
- 12.2.14. Fujifilm Toyama Chemical
- 12.2.15. Sofinnova Partners

13. 360 Degree Analyst View

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us